ERBB2 and breast cancer: BC expressing HER2 comprises about 15% of all cases [6], and treatment requires anti-HER2 monoclonal antibodies, namely, trastuzumab, sometimes associated with pertuzumab, as adjuvant or neoadjuvant therapy.